Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ASH
December 07, 2013 at 11:16 AM EST
Infinity Pharmaceuticals (NASDAQ: INFI ) today announced updated Phase 1 data from an ongoing study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with
